Bayer vardenafil NDA
Executive Summary
Bayer files vardenafil NDA for erectile dysfunction on Sept. 24. Approval of the phosphodiesterase-5 inhibitor could ease the setback caused by the Baycol withdrawal (1"The Pink Sheet" Aug. 13, p. 4)
You may also be interested in...
Baycol Withdrawal Gives Boost To Pravachol; Will Crestor NDA Be Affected?
Bristol-Myers Squibb's Pravachol is gaining share in the retail market in the early days following the withdrawal of Bayer's Baycol, prescription tracking data from ArcLight indicate.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials